

Effective Date: December 2, 2024

TEST CHANGE

2,3 Dinor-11Beta-Prostaglandin F2 Alpha, 24-Hour Urine 3002337, BETA PG U

0002001, B21711 0 0	
Specimen Requirements:	
Patient Preparation:	Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to specimen collection.
Collect:	24-hour urine. Refrigerate during collection.
Specimen Preparation:	From a well-mixed 24-hour collection transfer 5 mL urine to ARUP standard transport tubes. (Min: 2.74 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	Refrigerated. Also acceptable: Frozen.
Unacceptable Conditions:	
Remarks:	Collection duration and urine volume must be provided for testing. Total collection volume must be greater than 300 mL.
Stability:	Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 month
Methodology:	Quantitative Colorimetry/High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Varies
Reported:	9-15 days
Note:	Elevated levels of 2,3-dinor-11 beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.
CPT Codes:	84150
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	



Effective Date: December 2, 2024

By Report